Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010

Similar documents
BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

Common Antidepressant Medications for Adults

TREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD

90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR

Quick Guide to Common Antidepressants-Adults

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Children s Hospital Of Wisconsin

Duragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist

OXYCODONE IR (oxycodone)

SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816

MORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)

Xartemis XR (oxycodone / acetaminophen extended release)

Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None

Antidepressant Selection in Primary Care

Primary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

HYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.

BELBUCA (buprenorphine buccal film)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Change Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness

Major Depressive Disorder

Medications and Children Disorders

Depression in Late Life

Psychobiology Handout

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

Partners in Care Quick Reference Cards

Part 2: Pain and Symptom Management Depression

Antidepressants Choosing the Right One

Anti-Depressant Medications

RATIONALE FOR INCLUSION IN PA PROGRAM

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

Depression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE

Drugs for Emotional and Mood Disorders Chapter 16

Antidepressant Selection in Primary Care

RATIONALE FOR INCLUSION IN PA PROGRAM

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

Medications Guide: Public Speaking And Social Anxiety

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School

Depression Pharmacology. PHPP 517 (IT-III) Fall 2011

Depression in Pregnancy

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018

Treatment of Major Depressive Disorder

Nucynta IR. Nucynta IR (tapentadol immediate-release) Description

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Treating Depression in Adults

Levorphanol. Levorphanol Tartrate. Description

Levorphanol. Levorphanol Tartrate. Description

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

Antidepressant Pharmacology An Overview

Butrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017

Volume 4; Number 5 May 2010

Depression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms

RATIONALE FOR INCLUSION IN PA PROGRAM

3. Atypical antidepressants

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Schedule FDA & literature based indications

Belbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description

Psychotropic Medication Use in Dementia

Study Guidelines for Quiz #1

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

Hysingla ER. Hysingla ER (hydrocodone bitartrate) Description

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Antidepressant Treatment of Depression

Guide to Psychiatric Medications for Children and Adolescents

Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests

Introduction to Drug Treatment

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Duragesic patch. Duragesic patch (fentanyl patch) Description

Duragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019

Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018

Nortriptyline vs amitriptyline in elderly

Belbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016

Depression & Anxiety in Adolescents

Duragesic patch. Duragesic patch (fentanyl patch) Description

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

Mental Health Nursing: Mood Disorders. By Mary B. Knutson, RN, MS, FCP

Realities of Depression in Primary Care Setting

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)

Antidepressants and Sedatives. David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School

Educational Objectives: Outline. Relevant Disclosures. Managing Depression in Primary Care Lake Tahoe, August 2011

Chronic Pain Care Management in Primary Care 12/16/2010. Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences

Objectives. Diagnostic Criteria DSM 5. Before we begin I should tell you that. General Diagnostics for Anxiety Disorders 08/02/2014

Depression. University of Illinois at Chicago College of Nursing

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

Morphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),

Psychiatry in Primary Care: What is the Role of Pharmacist?

Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials

Antidepressant Agents Step Therapy and Quantity Limit Program Summary

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.

Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA

Transcription:

Pharmacologic Treatment of Depression Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010 1

Disclosure I have no conflicts or commercial interests related to this presentation 2

Objectives 1. Describe the common pharmacologic agents used to manage depression in the elderly population. 2. Discuss the efficacy, safety and tolerability of common pharmacologic agents used to manage depression in the elderly. 3. Examine the appropriate selection of antidepressant therapy for an elderly patient with specific symptoms and/or co-morbidities. 3

Goals of AD Therapy in the Elderly Symptom improvement Therapeutic response (50% decrease in symptoms) Therapeutic remission (asymptomatic) Reduction in disability Improved functional status Improved quality of life Complications: Relapse: in symptoms within 6 months of remission Recurrence: new episode >6 months after remission Resistance: no to partial response to trial of 2 or more antidepressants Rajji TK, Mulsant BH, Lotrich FE, et al. Use of antidepressants in late life depression. Drugs Aging 2008: 25(10):841-853. 4

Pharmacology Biochemical theory Antidepressant drugs work by: Increasing serotonin Increasing norepinephrine Increasing both 5

Influence of Age on AD Therapy Altered drug pharmacokinetics: Decreased rates of drug absorption and onset of action Increased elimination half-life of drugs Alterations in plasma protein binding Variable decrease in hepatic clearance Decreased renal clearance of active metabolites Rajji TK, Mulsant BH, Lotrich FE, et al. Use of antidepressants in late life depression. Drugs Aging 2008: 25(10):841-853. 6

Influence of Age on AD Therapy Altered receptor sensitivity or neurotransmission: Decreased baroreceptor reflex Increased serotonergic extrapyramidal effects Increased incidence of SIADH Noradrenergic effects of medication Anti-adrenergic effects of medication Anticholinergic effects of medication Rajji TK, Mulsant BH, Lotrich FE, et al. Use of antidepressants in late life depression. Drugs Aging 2008: 25(10):841-853. 7

Principles of Drug Selection Changes in pharmacokinetics and pharmacodynamics Comorbid medical and psychiatric conditions Concomitant drug therapy Expected side-effect profile Previous response to therapy (if known) Cost of therapy or formulary restrictions 8

Special Considerations in the Elderly All antidepressants are equally efficacious SSRIs are first line due to improved tolerability Start low and go slow Dose adjustment in renal impairment: mirtazapine Fewer drug interactions with: Citalopram, escitalopram, sertraline, venlafaxine, mirtazapine Compliance may be difficult to achieve Response time may be longer in elderly: >6-12 weeks Higher risk of relapse in elderly: continue >2 years after remission 9

Pre-Pharmacotherapy Evaluation History and physical Blood pressure (include orthostatic measurements) Liver and renal studies Electrocardiographic findings Left bundle branch block, bifasicular block, seconddegree AV block, QT prolongation, atrial fibrillation 10

Medications Associated with Depression Class CNS Agents Cardiovascular agents Chemotherapeutics Steroids Anticonvulsants Others Drugs Benzodiazepines, alcohol, levodopa, amantandine, major tranquilizers, stimulants (rebound) β-blockers, clonidine, methyldopa, prazosin, digitalis, procainamide, thiazides, hydralazine Vincristine, vinblastine, L-asparaginase, azathioprine, bleomycin, cisplatin, cyclophosphamide interferon, tamoxifen Prednisone, estrogen agents Primidone, phenytoin, phenobarbital, carbamazepine, ethosuximide Cimetidine, non-steroidal anti-inflammatory agents (NSAIDs), disulfiram, phenylephrine Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Physician 2004;69:237-2382. 11

Drug Classes for Depression Class SSRIs SNRIs TCAs MAOIs Others Drugs fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine venlafaxine, desvenlafaxine, duloxetine Tertiary amines: amitriptyline, doxepin, imipramine, Secondary amines: desipramine, nortriptyline phenelzine, tranylcypromine, selegiline mirtazapine, bupropion 12

Selective Serotonin Reuptake Inhibitors First-line therapy due to safety and tolerability Low potential for fatal overdose Low incidence of anticholinergic and sedative effects Little to no influence on cognition Few adverse cardiovascular side effects Once daily dosing Effective for mood and anxiety Common adverse effects: Nausea (slow titration, take with food) Diarrhea Anxiety Sleep disturbance Headache Sexual dysfunction (15-30%) 13

Other ADEs of SSRIs in Elderly Platelet dysfunction and gastrointestinal bleeding Apathy Anorexia Extrapyramidal symptoms Hyponatremia and SIADH (12-25%) Serotonin syndrome TCAs, MAOIs, tramadol, dextromethorphan, meperidine Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008;25(6):501-519. 14

SSRIs Drug Dose (mg/d) Comment Fluoxetine 10-60 Long half-life, once weekly dose available; many drug interactions; insomnia, wt loss, agitation, EPS; available in liquid; Beers list Sertraline 50-200 Insomnia, EPS Fluvoxamine 100-300 Many drug interactions; anticholinergic effects, wt loss; less sexual dysfunction Citalopram 20-60 Available in liquid; less EPS/bleeding risk Escitalopram 10-20 Limited dosing range Paroxetine Paroxetine CR 20-50 Many drug interactions; anticholinergic effects (dose dependent), EPS, sedation; available in liquid; withdrawal symptoms common Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Phys 2004;69:2374-2382. 15 Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008;25(6):501-519.

Selective Serotonin/NE Reuptake Inhibitors First or second-line therapy Dual mechanism Effective for mood and anxiety May be useful in treatment resistant depression Risk of serotonin syndrome combined with certain drugs Common adverse effects: Nausea Irritability Insomnia Sexual dysfunction Tremor 16

SNRIs Drug Dose (mg/d) Comment venlafaxine 75-225 Dose dependent hypertension; available in XR duloxetine 20-60 Many drug interactions; FDA: peripheral neuropathy Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Phys 2004;69:2374-2382. Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008;25(6):501-519. 17

Tricyclic Antidepressants (TCAs) Effective and inexpensive Beneficial in neuropathic pain Poorly tolerated in elderly due to extensive ADEs NOT first line therapy High fatality risk with overdose (cardiotoxicity) Common adverse effects: Sedation Cardiac conduction abnormalities Decreased seizure threshold Anticholinergic effects Orthostasis Confusion Weight gain 18

TCAs Drug Dose (mg/d) Comment Desipramine 100-200 Less anticholinergic effect, less sedation Nortriptyline 75-125 Less anticholinergic effect, less orthostasis Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Phys 2004;69:2374-2382. Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008;25(6):501-519. Unutzer J. Late-life depression. NEJM 2007;357;2269-2276. 19

Monoamine Oxidase Inhibitors Tranylcypromine, phenelzine, selegiline Side effect profile limits use in older adults Numerous drug-drug and drug food interactions Must comply with tyramine-free diet No diet restriction with selegiline at lower doses Meperidine, narcotics, decongestants Reserved for treatment resistant depression (3 rd line) Prescriber should be experienced with MAO-I use Adverse effects: Orthostasis 20

Bupropion Activity of dopamine and NE Generally safe and well-tolerated Dosage range: 200-300mg/d Available in SR and XL forms Useful in patients with lethargy, sedation, fatigue May be helpful in smoking cessation Lacks sexual side effects and weight gain Low risk of overdose Adverse effects: Seizures Irritability, anxiety, agitation Insomnia GI symptoms 21

Mirtazapine Serotonergic at low doses; noradrenergic at higher doses Dosage range: 15-45mg/HS Available in sublingual form Lacks sexual side effects Lacks significant drug interactions Low doses (<30mg): sedation & appetite stimulation Clearance reduced in renal impairment 22

Trazodone Not recommended as a primary antidepressant Adverse effects: Sedation Orthostasis Priapism (rare) Low doses (25-50mg/HS) may be useful for insomnia 23

Stimulants Methylphenidate, dexamphetamine, modafinil Data suggest usefulness in specific patient groups Terminally ill patients Medically ill elderly patients Apathy Potential advantages: Accelerated response Energizing effect Adverse effects: insomnia, anxiety, tachycardia, hypertension, tremor, HA, anorexia, wt loss, GI disturbances 24 Hardy SE. Methylphenidate for treatment of depressive symptoms, apathy, and fatigue In medically ill older adults and terminaly ill adults. Am J Geriatr Pharmacother 2009;7(1):34-59.

Target Sx and Comorbidity Considerations Symptom/Comorbidity Anxiety Insomnia Psychomotor retardation Weight loss BPH Dementia Parkinson s disease Seizure disorder Neuropathic pain Cardiac disease Drug Selection SSRI or SNRI Mirtazapine Bupropion or stimulants (methylphenidate) Mirtazapine Avoid TCAs SSRIs or venlafaxine; avoid TCAs and paroxetine Venlafaxine, bupropion; avoid TCAs, MAOIs, possibly SSRIs (if with MAOB-I) Avoid bupropion, TCAs Duloxetine SSRIs, bupropion; avoid TCAs, SSRIs + Ic antiarrhythmics, venlafaxine in HTN 25

Cost Considerations Drug Generic $4 Geriatric Considerations Fluoxetine Yes Y Long half-life, drug interactions Sertraline Yes N Paroxetine Yes Y Drug interactions, ADEs Citalopram Yes Y Well tolerated Escitalopram No N Venlafaxine Yes N Duloxetine No N Indication for neuropathic pain Desvenlafaxine No N Mirtazapine Yes N Sedation, weight gain Bupropion Yes N Seizure risk 26

Medication Adherence Non-adherence rate is as high as 40-75% Factors associated with non-adherence Attitudes, perceptions, preferences Beliefs about etiology of depression/treatment Patient/provider communication Cognitive impairment Substance abuse Polypharmacy Cost of treatment Social support Gender/race 27 Zivin K, Kales HC. Adherence to depression treatment in older adults: a narrative review. Drugs Aging 2008;25(7):559-571.

Patient Aversion to AD Therapy Fear of dependence Resistance to viewing depressive symptoms as a medical illness Concern that antidepressants will prevent natural sadness Prior negative experiences with medications for depressions Givens, JL, Datto CJ, Ruckdeschel K, et al. Older patients aversion to antidepressants: a qualitative study. J Gen Intern Med 2006;21:146-151. 28

Neutraceuticals for Depression St. John s Wort American ginseng Siberian ginseng Gotu kola Lavendar Schisandra Ginkgo biloba 29

St. John s Wort Hypericin inhibits monoamine oxidase Hypericin and hyperforin inhibit serotonin reuptake Effective in mild to moderate depression Numerous drug interactions Drug levels of: statins, TCAs, warfarin, nifedipine, cyclosporine, oral contraceptives, protease inhibitors, theophylline, digoxin Drug effect of: beta-2 agonists, benzodiazepines, SSRIs Phototoxicity 30

Summary Pharmacotherapy is effective in treating depression in older adults Goals of therapy are to achieve remission, improve functional status, and improve quality of life Drug selection in the older population is largely based on pharmacokinetics/pharmacodynamics, co-morbid conditions, concomitant drug therapy, drug side effect profiles, previous response to therapy, and cost 31

Trade Name Conversion Drug (Trade) Drug (Trade) Fluoxetine (Prozac) Amitriptyline (Elavil) Sertraline (Zoloft) Nortriptyline (Pamelor) Citalopram (Celexa) Desipramine (Norpramin) Escitalopram (Lexapro) Doxepin (Sinequan, Adapin) Fluvoxamine (Luvox) Imipramine (Tofranil) Paroxetine (Paxil) Clomipramine (Anafranil) Venlafaxine (Effexor) Phenelzine (Nardil) Desvenlafaxine (Pristiq) Tranylcypromine (Parnate) Duloxetine (Cymbalta) Selegilene (Emsam) Bupropion (Wellbutrin) Methylphenidate (Ritalin and others) Trazodone (Desyrel) Nefazodone (Serzone) 32

33 Questions